The questions Canadians actually ask about GLP-1s, peptides, cost, coverage, provider selection, and safety — grouped by topic and answered in plain language.
No. Flatland Health is an independent Canadian consumer-education publisher. We do not prescribe, dispense, or sell medications. We publish plain-language education and comparison content on Health Canada-authorized GLP-1 and peptide treatments, and we make referrals to Canadian telehealth clinics that prescribe those authorized medications.
Affiliate commissions from a small number of the Canadian telehealth providers we recommend. When you sign up with one via a link on this site, we may earn a commission at no extra cost to you. We only include providers that prescribe Health Canada-authorized medications, and we don't accept payment for placement or ranking. Full affiliate and editorial policy here.
Flatland Health is built in Moose Jaw, Saskatchewan. Access to healthcare — including GLP-1 prescribers — is different on the Prairies than in Toronto or Vancouver. Provincial drug plans, telehealth licensing, and shipping realities are Prairie-specific. We cover all of Canada, but we always keep Saskatchewan, Alberta, and Manitoba readers in mind.
Yes. Every medical claim on the site is sourced to primary Health Canada, provincial drug-plan, or peer-reviewed sources. Product names, indications, and prescribing criteria are checked against Health Canada's Drug Product Database. Corrections are welcomed via [email protected] and are dated on the affected page.
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating that helps regulate blood sugar and appetite. A GLP-1 receptor agonist is a medication that mimics that hormone. In Canada the two most common are semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Tirzepatide is technically a dual GLP-1 + GIP receptor agonist.
Same molecule — semaglutide — sold by Novo Nordisk under different brands. Ozempic is authorized by Health Canada for type 2 diabetes; Wegovy is authorized for chronic weight management. The pens, dosing schedules, and maximum doses are slightly different.
Same molecule — tirzepatide — by Eli Lilly. Mounjaro is the Canadian brand for type 2 diabetes; Zepbound is the brand for chronic weight management. Zepbound's Canadian availability is more recent than Mounjaro's.
Yes. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) all have valid Notices of Compliance from Health Canada. Flatland Health only covers Health Canada-authorized medications.
Not for the injectable forms as of early 2026. Novo Nordisk and Eli Lilly hold patent protection on semaglutide and tirzepatide in Canada into the late 2020s and early 2030s depending on the specific formulation.
Approximate cash prices as of early 2026: Ozempic ~$300–$400 per month, Wegovy ~$400–$550, Mounjaro ~$450–$600, Zepbound ~$500–$700. Prices vary by pharmacy, dose, and dispensing fees. Some telehealth clinics negotiate their own pharmacy pricing. Always confirm before you commit.
Ozempic and Mounjaro are typically covered only for type 2 diabetes patients who meet specific criteria (metformin usually needs to be tried first). Wegovy and Zepbound (weight-management authorizations) are generally not covered by provincial plans. See our provincial pages for Saskatchewan, Alberta, and Manitoba.
Some do, some don't. Many private plans cover Ozempic for type 2 diabetes; fewer cover Wegovy or Zepbound for weight management, and those that do usually require prior authorization. Ask HR for the drug list specific to your plan.
The nationwide clinics (Felix, Maple) generally ship anywhere with a Canadian postal code. Cold-chain shipping to rural addresses can take a day or two longer. Provider-specific delivery details are on each provider's own site — we link them from the directory.
Match on four factors: province coverage (they must be licensed where you live), goal (weight vs type 2 diabetes vs both), urgency (fast async intake vs structured 12-month program), and cost sensitivity (provincial-plan-covered visits vs private-pay). Our two-minute eligibility quiz walks you through it.
Not through a reputable Canadian prescriber. Weight-management GLP-1s (Wegovy, Zepbound) require a BMI of 30, or 27 with a related condition like high blood pressure, dyslipidemia, sleep apnea, or type 2 diabetes. Programs that skip that screen are not the ones we recommend.
Six good ones:
Canadian pharmacy compounding rules are strict. Compounded semaglutide is generally not a mainstream option through Canadian pharmacies the way it briefly was in the US during shortages. If a Canadian provider offers you a compounded version, ask exactly what they mean, where it's compounded, and under what authorization.
Nausea, constipation, and diarrhea are most common — usually worst in the first weeks of each dose step and improving as the body adapts. Less commonly: vomiting, fatigue, dizziness, burping, headache. Rare but serious: gallbladder issues, dehydration from severe vomiting, and pancreatitis. A reputable prescriber starts you at the lowest dose and titrates up slowly to keep side effects manageable.
Main contraindications: personal or family history of medullary thyroid carcinoma or MEN2 (boxed warning), prior serious pancreatitis, pregnancy or breastfeeding, severe gastroparesis or severe GI disease. Not exhaustive — your prescriber will do a full history.
Trial data (STEP-4, SURMOUNT-4) shows most people regain a significant portion of the weight lost within 12 months of stopping. GLP-1s work while you're on them; the metabolic effect largely fades when you stop. Long-term use is a real conversation to have with your prescriber.
No. GLP-1 medications are not recommended during pregnancy or breastfeeding. Most Canadian prescribers recommend stopping GLP-1s ahead of a planned pregnancy.
Most injectable wellness peptides marketed online do not have a Health Canada Notice of Compliance for those uses. Health Canada's April 2026 advisory warns against injecting peptides bought online from unauthorized sources — and that "research use only" labels do not make sales legal. Flatland Health does not cover RUO peptides. For weight and metabolic health, start with authorized GLP-1s via a licensed Canadian practitioner. See our peptide guide for how to verify drugs in the Drug Product Database; we do not claim Egrifta is currently an easy-to-obtain Canadian commercial product.
Two minutes. Seven questions. A personalized short-list of Canadian providers that actually serve your province.
Editorial + affiliate disclosure: Flatland Health is an independent Canadian publisher. Some links to telehealth providers are affiliate links — if you sign up, we may earn a commission at no extra cost to you. We only recommend clinics that prescribe Health Canada-authorized medications. Content is for education only and is not medical advice. Read the full disclosure →
